Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Flaviviridae Infections

ClinicalTrials.gov lists 2,809 trials for Flaviviridae Infections or a narrower condition beneath it. Merck Sharp & Dohme LLC has the most among industry and government lead sponsors, with 164.

MeSH D018178 Infections C01
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 384 Phase 1/2 Phase 1/2 69 Phase 2 Phase 2 459 Phase 2/3 Phase 2/3 54 Phase 3 Phase 3 421 Phase 4 Phase 4 331 Not applicable Not applicable 365 Observational Observational 719 Phase 1 Phase 1 384 Phase 1/2 Phase 1/2 69 Phase 2 Phase 2 459 Phase 2/3 Phase 2/3 54 Phase 3 Phase 3 421 Phase 4 Phase 4 331 Not applicable Not applicable 365 Observational Observational 719

Trials per phase

1 more section with rows

14 of the 2,809 trials are tagged with Flaviviridae Infections itself; the rest are tagged with a narrower condition beneath it.

Get the Flaviviridae Infections report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Flaviviridae Infections trials start? (34)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 4 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 187

1991: 1 trials (Observational 1) 1992: 1 trials (Observational 1) 1993: 2 trials (Observational 1, Phase 3 1) 1994: 1 trials (Observational 1) 1997: 3 trials (Observational 1, Phase 3 1, Phase 2/3 1) 1998: 5 trials (Observational 2, Phase 3 1, Phase 2/3 1, Phase 2 1) 1999: 5 trials (Observational 4, Phase 4 1) 2000: 12 trials (Observational 3, Phase 4 1, Phase 3 4, Phase 2 4) 2001: 23 trials (Observational 5, Not applicable 1, Phase 4 2, Phase 3 2, Phase 2 9, Phase 1/2 2, Phase 1 2) 2002: 47 trials (Observational 4, Phase 4 11, Phase 3 18, Phase 2/3 2, Phase 2 12) 2003: 48 trials (Observational 6, Not applicable 4, Phase 4 15, Phase 3 10, Phase 2 6, Phase 1/2 5, Phase 1 2) 2004: 66 trials (Observational 15, Not applicable 4, Phase 4 16, Phase 3 11, Phase 2/3 1, Phase 2 12, Phase 1/2 3, Phase 1 4) 2005: 121 trials (Observational 29, Not applicable 8, Phase 4 27, Phase 3 19, Phase 2/3 1, Phase 2 24, Phase 1/2 3, Phase 1 10) 2006: 98 trials (Observational 19, Not applicable 8, Phase 4 17, Phase 3 14, Phase 2/3 3, Phase 2 21, Phase 1/2 2, Phase 1 14) 2007: 119 trials (Observational 23, Not applicable 10, Phase 4 23, Phase 3 12, Phase 2/3 2, Phase 2 26, Phase 1/2 3, Phase 1 20) 2008: 116 trials (Observational 22, Not applicable 8, Phase 4 13, Phase 3 16, Phase 2 25, Phase 1/2 7, Phase 1 25) 2009: 146 trials (Observational 25, Not applicable 10, Phase 4 12, Phase 3 12, Phase 2/3 1, Phase 2 39, Phase 1/2 5, Phase 1 42) 2010: 144 trials (Observational 30, Not applicable 6, Phase 4 10, Phase 3 17, Phase 2/3 3, Phase 2 36, Phase 1/2 2, Phase 1 40) 2011: 187 trials (Observational 37, Not applicable 13, Phase 4 16, Phase 3 38, Phase 2/3 3, Phase 2 37, Phase 1/2 7, Phase 1 36) 2012: 183 trials (Observational 40, Not applicable 12, Phase 4 13, Phase 3 45, Phase 2/3 2, Phase 2 32, Phase 1/2 5, Phase 1 34) 2013: 149 trials (Observational 23, Not applicable 11, Phase 4 13, Phase 3 30, Phase 2/3 6, Phase 2 36, Phase 1/2 5, Phase 1 25) 2014: 155 trials (Observational 29, Not applicable 14, Phase 4 13, Phase 3 37, Phase 2/3 5, Phase 2 26, Phase 1/2 2, Phase 1 29) 2015: 175 trials (Observational 50, Not applicable 17, Phase 4 22, Phase 3 38, Phase 2/3 6, Phase 2 26, Phase 1/2 3, Phase 1 13) 2016: 176 trials (Observational 58, Not applicable 22, Phase 4 20, Phase 3 31, Phase 2/3 2, Phase 2 23, Phase 1/2 1, Phase 1 19) 2017: 151 trials (Observational 47, Not applicable 24, Phase 4 25, Phase 3 24, Phase 2/3 2, Phase 2 13, Phase 1/2 1, Phase 1 15) 2018: 125 trials (Observational 47, Not applicable 26, Phase 4 19, Phase 3 8, Phase 2/3 1, Phase 2 12, Phase 1/2 2, Phase 1 10) 2019: 119 trials (Observational 40, Not applicable 33, Phase 4 13, Phase 3 8, Phase 2/3 2, Phase 2 12, Phase 1/2 1, Phase 1 10) 2020: 71 trials (Observational 22, Not applicable 27, Phase 4 9, Phase 3 1, Phase 1/2 3, Phase 1 9) 2021: 61 trials (Observational 22, Not applicable 20, Phase 4 4, Phase 3 3, Phase 2/3 2, Phase 2 5, Phase 1/2 2, Phase 1 3) 2022: 65 trials (Observational 21, Not applicable 22, Phase 4 8, Phase 3 3, Phase 2 5, Phase 1 6) 2023: 59 trials (Observational 27, Not applicable 21, Phase 3 2, Phase 2/3 2, Phase 2 5, Phase 1/2 1, Phase 1 1) 2024: 58 trials (Observational 26, Not applicable 16, Phase 4 4, Phase 3 2, Phase 2 4, Phase 1/2 1, Phase 1 5) 2025: 48 trials (Observational 22, Not applicable 9, Phase 4 2, Phase 3 7, Phase 2/3 2, Phase 2 3, Phase 1/2 1, Phase 1 2)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 34
2025 48
2024 58
2023 59
2022 65
2021 61
2020 71
2019 119
2018 125
2017 151

Showing 10 of 34 earlier years.

Start your 14-day trial Email me all 34 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 44 trials starting in 2026 and about 44 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 35 months from start to primary completion across 59 trials still running at the 2026-10-09 snapshot; registered median of 20 months across 2,119 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Flaviviridae Infections trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 384
Phase 1/2 69
Phase 2 459
Phase 2/3 54
Phase 3 421
Phase 4 331
Not applicable 365
Observational 719
Expanded access 7

How many Flaviviridae Infections trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 37
Recruiting 78
Enrolling by invitation 9
Active, not recruiting 41
Available 1

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Flaviviridae Infections trials? (14)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Merck Sharp & Dohme LLC 164
Gilead Sciences 119
AbbVie 91
Bristol-Myers Squibb 91
National Institute of Allergy and Infectious Diseases (NIAID) 90

Showing 5 of 14 sponsors.

Start your 14-day trial Email me all 14 sponsors as a PDF

Which drugs are being tested for Flaviviridae Infections? (5)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
PEGinterferon alfa-2a 177
Peginterferon Alfa-2B 91
Daclatasvir 73
TMC435 67
Boceprevir 39

Interventions as named in the registry (10)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Ribavirine 551
Sofosbuvir, Sovaldi 108
Telaprevir 54
Ritonavir (RTV) low 34
dasabuvir 8 weeks 31

Showing 5 of 10 interventions.

Start your 14-day trial Email me all 10 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Flaviviridae Infections trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Anaemia 629 121
Dengue Fever 603 7
Appendicitis 601 78
Pneumonia 541 154
Gastroenteritis 423 82

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Flaviviridae Infections? (5)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Vaccine-induced T cell responses control Orthoflavivirus challenge infection without neutralizing antibodies in humans. Nature microbiology 2025 Yes
Reduction in hepatitis C-related liver disease associated with GB virus C in human immunodeficiency virus coinfection. Gastroenterology 2007 Yes
GB virus C: insights into co-infection. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2005 Yes
Persistent GB virus C infection and survival in HIV-infected men. The New England journal of medicine 2004 Yes
Resistance to HIV infection. Journal of urban health : bulletin of the New York Academy of Medicine 2006 No

Sub-conditions in MeSH (2)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages